(Recording) ECHO 3: Weightier Matters - Intensive Lifestyle Interventions

Each ECHO will have a live and on-demand component; those who participate in the live ECHO may receive credit from the live event but are not eligible to also receive credit for the on-demand webinar. For those who registered for the live event but did not attend, your enrollment has been shifted to this course.

We are pleased to participate in Project ECHO: Approaches to Long-Term Weight Loss and Obesity Care - a live, interactive seminar series. The third ECHO in this series will focus on lifestyle interventions and total diet meal replacement, with diet comparison provided, with Amy Rothberg, MD, PhD. The live ECHO took place on September 22, 2020; this course contains the recording from the live event, and is eligible for CME from 9/30/2020-12/31/2022. 

Please note that to participate in this ECHO, you must complete registration for the Project ECHO program and the pre-survey for this program after clicking 'Register.'

About This ECHO

By the end of this ECHO, participants will be able to:

  • Review the characteristics of successful lifestyle intervention
  • Familiarize yourself with the concept and approach of lifestyle interventions incorporating TDR
  • Evaluate the role of TDR as strategy for weight loss and improved clinical outcomes (lessons from OPTIWIN, DiRECT and DROPLET studies)

Supporting Article:
Ard JD, Lewis KH, Rothberg A, et al. Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study. Obesity (Silver Spring). 2019;27(1):22-29. doi:10.1002/oby.22303

Target Audience

This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, obesity and associated diseases. Additionally, this program may be of interest to primary care professionals and advance practice professionals who treat patients with obesity.

Learning Objectives

By the end of this ECHO, participants will be able to:

  • Review the characteristics of successful lifestyle intervention
  • Familiarize yourself with the concept and approach of lifestyle interventions incorporating TDR
  • Evaluate the role of TDR as strategy for weight loss and improved clinical outcomes (lessons from OPTIWIN, DiRECT and DROPLET studies)

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Obesity
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
08/31/2020
Course expires: 
12/31/2022
Rating: 
0

Faculty 

Amy E. Rothberg, MD, PhD 
University of Michigan 

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: Amy E. Rothberg, MD, PhD - Self: Rhythm, Consultant/Advisory; Spouse: Merck, Data Safety Monitoring Board. 

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewers reported no relevant financial relationships: Beret A. Casey, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE:

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT:

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT:

This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. 

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit may be claimed from 9/30/2020-12/31/2022.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation